[Allogeneic peripheral blood stem cell transplantation].
Allogeneic peripheral blood stem cell transplantation (allo-PBSCT) has been increasingly used as an alternative to allogeneic bone marrow transplantation (allo-BMT). In comparison with allo-BMT, preliminary results indicate that rapid hematopoietic engraftment can be obtained, and there is no increase in the incidence and severity of acute GVHD after allo-PBSCT. Furthermore, general anesthesia is not required to collect a sufficient number of PBSCT, which are usually mobilized by G-CSF administration. Therefore, allo-BMT will be replaced by allo-PBSCT in near future.
Harada
M
M
Dept. of Internal Medicine II, Okayama University Medical School.
D000328:Adult; D000818:Animals; D016026:Bone Marrow Transplantation; D006086:Graft vs Host Disease / Q000209:etiology; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007938:Leukemia / Q000628:therapy; D014019:Tissue Donors; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
D016179:Granulocyte Colony-Stimulating Factor